Dabur Pharma Ltd's oncology unit has received the approval from US Food and Drug Administrator (USFDA) for selling 'Mitoxantrone Hydrochloride in various strengths’.

'Mitoxantrone Hydrochloride is indicated for reducing neurologic disability and /or the frequency of clinical relapses in patients with secondary chronic progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Dabur Pharma Ltd operates in Europe and other overseas markets through its fully owned subsidiary, Dabur Oncology Plc.